CANSINOBIO(06185): TB vaccine for inhalation initiated Phase I clinical trials in Indonesia and completed the enrollment of the first subject.

CANSINOBIO (06185) announces that the inhaled tuberculosis vaccine (type 5 adenovirus vector) developed by the company has recently started Phase I clinical trials in Indonesia and has completed the enrollment of the first subjects in the Phase I clinical trial. Currently, BCG vaccine is the only vaccine available globally for preventing tuberculosis, widely administered worldwide, playing an important role in preventing tuberculosis in infants and young children. However, the protective effect of BCG vaccine diminishes over time and cannot be enhanced by booster vaccinations. To address this deficiency, the company has developed the first-generation innovative tuberculosis booster vaccine for individuals vaccinated with BCG. The tuberculosis booster vaccine has completed Phase Ia and Ib clinical trials in Canada, demonstrating the safety and effectiveness of the tuberculosis booster vaccine as a candidate vaccine and as a BCG booster vaccine, as well as the superiority of mucosal immunity. Based on the technology accumulated from the development of inhaled COVID-19 vaccines, the company has established a complete inhaled pharmaceutical and quality control system, upgraded the first-generation product, added antigen components, and developed an inhaled tuberculosis booster vaccine. It is delivered through nebulization inhalation, which is expected to stimulate pulmonary immune responses, eliminate tuberculosis bacteria, control latent infections, and achieve preventive effects against infection. The Phase I clinical trial is being conducted in Indonesia, aiming to investigate the safety and immunogenicity of a single dose of the inhaled tuberculosis booster vaccine in adults aged 18 to 49.